JP2020514321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514321A5 JP2020514321A5 JP2019541287A JP2019541287A JP2020514321A5 JP 2020514321 A5 JP2020514321 A5 JP 2020514321A5 JP 2019541287 A JP2019541287 A JP 2019541287A JP 2019541287 A JP2019541287 A JP 2019541287A JP 2020514321 A5 JP2020514321 A5 JP 2020514321A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- immunomodulatory
- pseudouridine
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 33
- 230000002519 immonomodulatory effect Effects 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 230000001225 therapeutic effect Effects 0.000 claims 17
- 150000002632 lipids Chemical class 0.000 claims 14
- 239000002105 nanoparticle Substances 0.000 claims 13
- 108091028732 Concatemer Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 102100030708 GTPase KRas Human genes 0.000 claims 7
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 108700020796 Oncogene Proteins 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 7
- 206010069755 K-ras gene mutation Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000007385 chemical modification Methods 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 102200006531 rs121913529 Human genes 0.000 claims 5
- 102200006538 rs121913530 Human genes 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102200006532 rs112445441 Human genes 0.000 claims 4
- 102200006539 rs121913529 Human genes 0.000 claims 4
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 3
- 108700019961 Neoplasm Genes Proteins 0.000 claims 3
- 102000048850 Neoplasm Genes Human genes 0.000 claims 3
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000043276 Oncogene Human genes 0.000 claims 2
- 229930185560 Pseudouridine Natural products 0.000 claims 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 102200006537 rs121913529 Human genes 0.000 claims 2
- 102200006540 rs121913530 Human genes 0.000 claims 2
- 102200006541 rs121913530 Human genes 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 claims 1
- MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 claims 1
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims 1
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims 1
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 claims 1
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 claims 1
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 claims 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 claims 1
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 claims 1
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 claims 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 claims 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 claims 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000006023 anti-tumor response Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000005000 reproductive tract Anatomy 0.000 claims 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
- 229940045145 uridine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023068492A JP2023103250A (ja) | 2017-02-01 | 2023-04-19 | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453465P | 2017-02-01 | 2017-02-01 | |
| US62/453,465 | 2017-02-01 | ||
| US201762467063P | 2017-03-03 | 2017-03-03 | |
| US62/467,063 | 2017-03-03 | ||
| US201762490523P | 2017-04-26 | 2017-04-26 | |
| US62/490,523 | 2017-04-26 | ||
| US201762541571P | 2017-08-04 | 2017-08-04 | |
| US62/541,571 | 2017-08-04 | ||
| PCT/US2018/016510 WO2018144775A1 (en) | 2017-02-01 | 2018-02-01 | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023068492A Division JP2023103250A (ja) | 2017-02-01 | 2023-04-19 | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514321A JP2020514321A (ja) | 2020-05-21 |
| JP2020514321A5 true JP2020514321A5 (enExample) | 2021-08-12 |
Family
ID=61244714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541287A Pending JP2020514321A (ja) | 2017-02-01 | 2018-02-01 | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
| JP2023068492A Pending JP2023103250A (ja) | 2017-02-01 | 2023-04-19 | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023068492A Pending JP2023103250A (ja) | 2017-02-01 | 2023-04-19 | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190351039A1 (enExample) |
| EP (1) | EP3576780A1 (enExample) |
| JP (2) | JP2020514321A (enExample) |
| KR (1) | KR20190110612A (enExample) |
| CN (2) | CN110430894A (enExample) |
| AU (1) | AU2018214556A1 (enExample) |
| BR (1) | BR112019015797A2 (enExample) |
| CA (1) | CA3051252A1 (enExample) |
| CL (1) | CL2019002134A1 (enExample) |
| CO (1) | CO2019009234A2 (enExample) |
| EA (1) | EA201991804A1 (enExample) |
| IL (1) | IL268361A (enExample) |
| MX (2) | MX2019009070A (enExample) |
| SG (1) | SG11201906969PA (enExample) |
| WO (1) | WO2018144775A1 (enExample) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| US12150980B2 (en) | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| DK3350157T3 (da) | 2015-09-17 | 2022-02-14 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| MA52645B1 (fr) | 2015-10-22 | 2022-06-30 | Modernatx Inc | Vaccins contre le virus respiratoire |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| CN117731769A (zh) | 2015-10-22 | 2024-03-22 | 摩登纳特斯有限公司 | 用于水痘带状疱疹病毒(vzv)的核酸疫苗 |
| MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
| AU2016377681B2 (en) | 2015-12-22 | 2021-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CN109937253B (zh) | 2016-09-14 | 2023-06-30 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP3576780A1 (en) | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| AU2018234692B2 (en) * | 2017-03-15 | 2022-06-02 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11752206B2 (en) * | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| WO2019152557A1 (en) * | 2018-01-30 | 2019-08-08 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| BR112020024292A2 (pt) | 2018-06-06 | 2021-03-02 | Massachusetts Institute Of Technology | rna circular para translação em células eucarióticas |
| EP3826669A2 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| EP3863645A4 (en) * | 2018-09-13 | 2022-11-16 | ModernaTX, Inc. | MODIFIED mRNA FOR THE TREATMENT OF FAMILY PROGRESSIVE INTRAHEPATIC CHOLESTASIS DISORDERS |
| CN112702994A (zh) * | 2018-09-18 | 2021-04-23 | 根特大学 | 治疗性纳米颗粒及其使用方法 |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| TW202039534A (zh) * | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| CA3176660A1 (en) * | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| EP3938507A4 (en) | 2019-03-11 | 2023-02-22 | ModernaTX, Inc. | PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| IL288284B2 (en) | 2019-05-22 | 2024-06-01 | Massachusetts Inst Technology | Circular rna compositions and methods |
| CA3154618A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| JP7650873B2 (ja) | 2019-10-09 | 2025-03-25 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの組成物、方法および使用 |
| CA3157859A1 (en) * | 2019-10-15 | 2021-04-22 | Modernatx, Inc. | Mrnas encoding immune modulating polypeptides and uses thereof |
| EP4058578A2 (en) * | 2019-11-12 | 2022-09-21 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| AU2020382378A1 (en) * | 2019-11-15 | 2022-06-30 | Daiichi Sankyo Company, Limited | Nucleic acid lipid particle vaccine encapsulating HPV mRNA |
| JP2023504568A (ja) | 2019-12-04 | 2023-02-03 | オルナ セラピューティクス インコーポレイテッド | 環状ｒｎａ組成物及び方法 |
| KR102410556B1 (ko) * | 2020-01-16 | 2022-06-20 | 아주대학교산학협력단 | 미토콘드리아 타겟팅용 펩타이드 |
| JP2023512072A (ja) * | 2020-01-30 | 2023-03-23 | モデルナティエックス インコーポレイテッド | 代謝リプログラミングポリペプチドをコードするｍＲＮＡ及びその使用 |
| CN111440825A (zh) * | 2020-04-07 | 2020-07-24 | 嘉晨西海(杭州)生物技术有限公司 | 一种脂质体载mRNA的方法 |
| TW202204622A (zh) * | 2020-04-09 | 2022-02-01 | 大陸商蘇州艾博生物科技有限公司 | 針對冠狀病毒之核酸疫苗 |
| BR112022020407A2 (pt) | 2020-04-09 | 2023-05-02 | Verve Therapeutics Inc | Edição base do pcsk9 e métodos de uso do mesmo para tratamento de doenças |
| JP2023522249A (ja) | 2020-04-22 | 2023-05-29 | ビオンテック・ソシエタス・エウロパエア | コロナウイルスワクチン |
| JP7460094B2 (ja) | 2020-04-24 | 2024-04-02 | ジェネクシン・インコーポレイテッド | 子宮頸がんの治療方法 |
| US12188060B2 (en) | 2020-05-15 | 2025-01-07 | Crispr Therapeutics Ag | Messenger RNA encoding Cas9 for use in genome-editing systems |
| WO2022035621A1 (en) * | 2020-07-31 | 2022-02-17 | Combined Therapeutics, Inc. | Compositions and methods for improved vaccination |
| EP4194006A4 (en) * | 2020-08-04 | 2024-12-04 | Progeneer Inc. | mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP2023546133A (ja) * | 2020-10-14 | 2023-11-01 | アールエヌエーイミューン、インコーポレイテッド | 汎ＲＡＳ ｍＲＮＡがんワクチン |
| JP7644229B2 (ja) | 2020-10-20 | 2025-03-11 | エスティー ファーム カンパニー リミテッド | ５’－キャッピングされたｒｎａ合成用オリゴヌクレオチド |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| JP2023551204A (ja) * | 2020-11-20 | 2023-12-07 | シンク・セラピューティクス・インコーポレイテッド | 最適化ペプチドワクチンの組成物および方法 |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) * | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| MX2023007137A (es) * | 2020-12-21 | 2023-08-28 | Beam Therapeutics Inc | Nanomateriales que comprenden acetales unidos a ésteres. |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| EP4293043A4 (en) * | 2021-02-10 | 2025-09-10 | Shanghai Genbase Biotechnology Co Ltd | EPITOPE PEPTIDE OF THE RAS G13D MUTANT AND T LYMPHOCYTE RECEPTOR RECOGNIZING THE RAS G13D MUTANT |
| AU2022230446A1 (en) * | 2021-03-05 | 2023-09-21 | Modernatx, Inc. | Vlp enteroviral vaccines |
| CN117479951A (zh) * | 2021-03-26 | 2024-01-30 | 转化基因组学研究所 | 用于新抗原疫苗的方法和化合物 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| WO2022240960A1 (en) | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
| CN113264842B (zh) * | 2021-07-21 | 2022-03-01 | 苏州科锐迈德生物医药科技有限公司 | 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| CN115703713B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| EP4402121A1 (en) * | 2021-09-14 | 2024-07-24 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| WO2023061460A1 (zh) * | 2021-10-15 | 2023-04-20 | 厦门赛诺邦格生物科技股份有限公司 | 含氮的阳离子脂质及其应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| EP4452298A4 (en) * | 2021-12-22 | 2025-11-19 | Memorial Sloan Kettering Cancer Center | CELLS EXPRESSING FAS LIGAND AND CFLIP POLYPEPTIDES AND THEIR USES |
| CN116376942A (zh) * | 2021-12-31 | 2023-07-04 | 广州国家实验室 | mRNA疫苗 |
| US20250101078A1 (en) * | 2022-01-21 | 2025-03-27 | T-Knife Gmbh | Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
| MX2024011238A (es) * | 2022-03-16 | 2024-09-19 | Boehringer Ingelheim Int | Antigenos tumorales, compuestos que comprenden los antigenos tumorales kras, tpx2 o aurka y usos de los mismos. |
| CN115521220B (zh) * | 2022-05-19 | 2023-06-09 | 仁景(苏州)生物科技有限公司 | 长链烷基酯胺类化合物及其制备方法和在核酸递送方面的应用 |
| CN115286674A (zh) * | 2022-06-13 | 2022-11-04 | 湖北英纳氏生物科技有限公司 | 一种阳离子脂质体及其制备方法 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| WO2024102332A1 (en) * | 2022-11-07 | 2024-05-16 | Himv Llc | Vaccine compositions comprising a neoantigen of kras |
| WO2024107827A1 (en) * | 2022-11-16 | 2024-05-23 | The Broad Institute, Inc. | Therapeutic exploitation of sting channel activity |
| JP2025538524A (ja) * | 2022-11-22 | 2025-11-28 | エリクサージェン セラピューティクス，インコーポレイティド | 癌免疫療法のための抗原 |
| WO2024109866A1 (zh) | 2022-11-24 | 2024-05-30 | 苏州艾博生物科技有限公司 | 提高蛋白表达量的utr分子 |
| EP4640828A1 (en) * | 2022-12-23 | 2025-10-29 | Hanmi Pharm. Co., Ltd. | Antigenic peptide having multiple kras variant peptides linked thereto, nucleic acid encoding the same, and use thereof |
| WO2024147556A1 (ko) * | 2023-01-05 | 2024-07-11 | 의료법인 명지의료재단 | K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물 |
| WO2024151877A2 (en) | 2023-01-11 | 2024-07-18 | Engage Biologics Inc. | Non-viral expression systems and methods of use thereof |
| WO2024199359A1 (zh) * | 2023-03-28 | 2024-10-03 | 江苏瑞科生物技术股份有限公司 | 包含环二核苷酸分子的脂质体佐剂系统及其制备方法 |
| WO2024211447A1 (en) * | 2023-04-03 | 2024-10-10 | Chrysalis Biotherapeutics | Tp508 mrnas |
| CN117604031B (zh) * | 2023-04-20 | 2025-05-09 | 龙岩学院 | 一种猫冠状病毒S蛋白mRNA的体外转录系统及其构建方法 |
| TW202530174A (zh) * | 2023-10-19 | 2025-08-01 | 大陸商仁景（蘇州）生物科技有限公司 | 用於遞送的脂質化合物及脂質奈米顆粒 |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| KR20250148433A (ko) * | 2024-03-29 | 2025-10-14 | 한미약품 주식회사 | 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도 |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613481D0 (en) | 1986-06-04 | 1986-07-09 | Diatech Ltd | Translation of mrna |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2284210B (en) | 1993-11-26 | 1997-11-12 | British Tech Group | Translational enhancer DNA from a kinesin gene |
| AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| US6503503B1 (en) | 1997-05-13 | 2003-01-07 | Duke University | Allogeneic cellular vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| US20060009633A9 (en) | 1997-11-13 | 2006-01-12 | Genset, S.A. | Complementary DNAs encoding proteins with signal peptides |
| NO309798B1 (no) | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| DE50214201D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung |
| EP2390328A1 (en) | 2001-09-28 | 2011-11-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| AU2002349784A1 (en) | 2001-12-03 | 2003-06-17 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| GB0221574D0 (en) | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| WO2004037284A1 (en) | 2002-10-22 | 2004-05-06 | Sanofi Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
| EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| ES2524018T3 (es) | 2006-01-05 | 2014-12-03 | The Ohio State University Research Foundation | Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares |
| EP2487260B1 (en) | 2006-01-05 | 2015-07-08 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
| EP2522747A1 (en) | 2006-03-02 | 2012-11-14 | The Ohio State University | MicroRNA expression profile associated with pancreatic cancer |
| CN101448848B (zh) * | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
| AU2007299828C1 (en) | 2006-09-19 | 2014-07-17 | Interpace Diagnostics, Llc | MicroRNAs differentially expressed in pancreatic diseases and uses thereof |
| JP5501766B2 (ja) | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン |
| CN101622350A (zh) | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为干预治疗靶标的miR-126调控基因和通路 |
| WO2008147974A1 (en) | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
| WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| EP2514762B1 (en) | 2007-07-13 | 2015-04-08 | The Johns Hopkins University | B7-DC variants |
| BRPI0813621A2 (pt) | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| HUE029164T2 (hu) | 2007-09-14 | 2017-02-28 | Univ Brussel Vrije | Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra |
| WO2009046738A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| US20100323357A1 (en) | 2007-11-30 | 2010-12-23 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer |
| WO2009111088A2 (en) | 2008-01-02 | 2009-09-11 | The Johns Hopkins University | Antitumor immunization by liposomal delivery of vaccine to the spleen |
| US20090263803A1 (en) | 2008-02-08 | 2009-10-22 | Sylvie Beaudenon | Mirnas differentially expressed in lymph nodes from cancer patients |
| US20110052502A1 (en) | 2008-02-28 | 2011-03-03 | The Ohio State University Research Foundation | MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| WO2009149539A1 (en) | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
| WO2010017248A2 (en) | 2008-08-04 | 2010-02-11 | University Of Miami | Sting (stimulator of interferon genes), a regulator of innate immune responses |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2010055487A2 (en) | 2008-11-13 | 2010-05-20 | Koninklijke Philips Electronics N.V. | Compositions and methods for micro-rna expession profiling of colorectal cancer |
| US20120053224A1 (en) | 2008-12-10 | 2012-03-01 | Universitat Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| EP2246433A1 (de) * | 2009-04-30 | 2010-11-03 | Mologen AG | Concatemere zur Immunmodulation |
| EP2427574A2 (en) | 2009-05-08 | 2012-03-14 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
| KR20230098713A (ko) | 2009-06-10 | 2023-07-04 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
| KR102315754B1 (ko) | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| MX341989B (es) * | 2010-08-31 | 2016-09-09 | Novartis Ag * | Liposomas pequeños para el suministro de arn que codifica el inmunogeno. |
| RS63315B1 (sr) * | 2010-08-31 | 2022-07-29 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| PL2633034T3 (pl) | 2010-10-26 | 2018-05-30 | Friedrich-Alexander-Universität Erlangen-Nürnberg | KOMÓRKI DENDRYTYCZNE Z PODDANYM MANIPULACJI SZLAKIEM SYGNAŁOWYM NFkB |
| AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| US20140113978A1 (en) | 2011-05-01 | 2014-04-24 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| US20130042333A1 (en) | 2011-05-06 | 2013-02-14 | Jean-Gabriel JUDDE | Markers for cancer prognosis and therapy and methods of use |
| EP3569607A1 (en) | 2011-05-11 | 2019-11-20 | Exosome Diagnostics, Inc. | Nucleic acid extraction from heterogeneous biological materials |
| EP2710136A4 (en) * | 2011-05-17 | 2015-01-21 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND USE METHOD FOR NON-HUMAN SPINE |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| MX360823B (es) | 2011-05-24 | 2018-11-16 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacunas individualizadas para el cancer. |
| CA3198966A1 (en) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Cleavable lipids |
| ES2610245T3 (es) | 2011-07-15 | 2017-04-26 | Leo Pharma A/S | Perfilado de microARN para el diagnóstico en linfoma cutáneo de células T (CTCL) |
| WO2013033640A1 (en) | 2011-09-01 | 2013-03-07 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| EP2753345B1 (en) | 2011-09-06 | 2016-07-13 | Agency For Science, Technology And Research | Polypeptide vaccine |
| WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| CA2856742A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| KR20140102759A (ko) * | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| CN103547683A (zh) * | 2012-03-22 | 2014-01-29 | 耶鲁大学 | Kras突变和肿瘤生物学 |
| AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| EP2844756A4 (en) | 2012-04-30 | 2016-02-24 | Glen N Barber | MODULATION OF IMMUNE REACTIONS |
| EP2847333B1 (en) * | 2012-05-09 | 2025-07-30 | Gradalis, Inc. | Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations |
| AU2013271375B2 (en) | 2012-06-08 | 2018-03-22 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
| US9913907B2 (en) * | 2012-07-16 | 2018-03-13 | Kyowa Hakko Kirin Co., Ltd. | RNAi pharmaceutical composition for suppressing expression of KRAS gene |
| US10973892B2 (en) | 2012-09-04 | 2021-04-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| WO2014039961A1 (en) | 2012-09-07 | 2014-03-13 | University Of Miami | Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| JP6484558B2 (ja) | 2012-11-28 | 2019-03-13 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | 癌ワクチンの組み合せ物 |
| HK1217215A1 (zh) | 2013-01-17 | 2016-12-30 | Modernatx, Inc. | 用於改变细胞表型的信号传感器多核苷酸 |
| US10137182B2 (en) | 2013-02-14 | 2018-11-27 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CA2898130A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Vaccines with biomolecular adjuvants |
| WO2014166501A2 (en) | 2013-04-10 | 2014-10-16 | Skau Aps | Use of immune suppressive peptides as adjuvants |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| ES2822584T3 (es) | 2013-05-03 | 2021-05-04 | Univ California | Inducción de dinucleótidos cíclicos del interferón tipo I |
| WO2014189806A1 (en) | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
| US9642830B2 (en) | 2013-10-21 | 2017-05-09 | Drexel University | Use of sting agonists to treat hepatitis B virus infection |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| EP3071209A4 (en) | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
| US9775892B2 (en) * | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| US10421971B2 (en) | 2014-01-15 | 2019-09-24 | The University Of Chicago | Anti-tumor therapy |
| WO2015123532A1 (en) * | 2014-02-16 | 2015-08-20 | Globeimmune, Inc. | Ras g12r immunotherapy for ras mutation-positive cancers |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| AU2015231461B2 (en) | 2014-03-17 | 2021-09-09 | Tapimmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
| DK4023249T3 (da) * | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| US11624093B2 (en) * | 2014-04-24 | 2023-04-11 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| CN106414493A (zh) * | 2014-05-06 | 2017-02-15 | 塔格瓦克斯公司 | 包含突变的ras肽和化疗剂的肽疫苗 |
| HRP20221536T1 (hr) | 2014-06-25 | 2023-02-17 | Acuitas Therapeutics Inc. | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina |
| EP3197490B1 (en) | 2014-09-26 | 2023-06-21 | Bavarian Nordic A/S | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| EP3273944B1 (en) | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| EP3289083A4 (en) | 2015-04-27 | 2018-12-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| CR20200476A (es) | 2015-05-20 | 2020-12-02 | Dana Farber Cancer Inst Inc | ANTÍGENOS COMPARTIDOS (Divisional 2017-0584) |
| CA2989157A1 (en) | 2015-06-11 | 2016-12-15 | University Of Miami | Cancer treatment and diagnosis |
| CN107922472A (zh) * | 2015-06-16 | 2018-04-17 | 塔格瓦克斯公司 | Ras蛋白的突变的片段 |
| WO2016203025A1 (en) | 2015-06-17 | 2016-12-22 | Curevac Ag | Vaccine composition |
| EP4218805A1 (en) * | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| US12150980B2 (en) * | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| US20180221503A1 (en) | 2015-07-31 | 2018-08-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
| DK3350157T3 (da) * | 2015-09-17 | 2022-02-14 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| US10322177B2 (en) | 2015-10-07 | 2019-06-18 | Nant Holdings Ip, Llc | Activation of immune-related signaling pathways in cells via optofection |
| US11623001B2 (en) | 2015-10-12 | 2023-04-11 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| EP3365006A1 (en) | 2015-10-19 | 2018-08-29 | Cadila Healthcare Limited | New adjuvant and vaccine composition containing the same |
| CN114404581A (zh) * | 2015-10-22 | 2022-04-29 | 摩登纳特斯有限公司 | 癌症疫苗 |
| PT3368507T (pt) | 2015-10-28 | 2023-02-07 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
| EP3393511A1 (en) | 2015-12-21 | 2018-10-31 | La Jolla Institute for Allergy and Immunology | Leveraging immune memory from common childhood vaccines to fight disease |
| EP3400005A1 (en) | 2016-01-08 | 2018-11-14 | Vaccibody AS | Neoepitope rna cancer vaccine |
| US20180000912A1 (en) | 2016-03-04 | 2018-01-04 | New York University | Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity |
| WO2017177204A1 (en) | 2016-04-09 | 2017-10-12 | La Jolla Institute For Allergy And Immunology | Leveraging immune memory from common childhood vaccines to fight disease |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| EP3452083A4 (en) | 2016-05-04 | 2020-01-01 | ImmunoVaccine Technologies Inc. | VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, NEOANTIGEN AND HYDROPHOBIC SUPPORT, AND METHODS OF USE THEREOF |
| AU2017268822B2 (en) | 2016-05-27 | 2020-03-26 | Etubics Corporation | Neoepitope vaccine compositions and methods of use thereof |
| EP3471778A4 (en) | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS |
| PL3488443T3 (pl) | 2016-07-20 | 2021-12-20 | BioNTech SE | Selekcja neoepitopów jako swoistych dla choroby celów dla terapii o zwiększonej skuteczności |
| AU2017315321A1 (en) | 2016-08-23 | 2019-04-11 | Mary P. Mccourt | Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells |
| RU2765874C2 (ru) | 2016-10-26 | 2022-02-04 | МОДЕРНАТиЭкс, ИНК. | Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения |
| CA3039356A1 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| WO2018102585A1 (en) | 2016-11-30 | 2018-06-07 | Advaxis, Inc. | Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations |
| MX2019005685A (es) | 2016-11-30 | 2019-09-04 | Advaxis Inc | Composiciones inmunogenicas contra mutaciones de cancer recurrentes y metodos de uso de las mismas. |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| EP3576780A1 (en) | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
-
2018
- 2018-02-01 EP EP18706040.5A patent/EP3576780A1/en active Pending
- 2018-02-01 EA EA201991804A patent/EA201991804A1/ru unknown
- 2018-02-01 AU AU2018214556A patent/AU2018214556A1/en not_active Abandoned
- 2018-02-01 US US16/482,473 patent/US20190351039A1/en not_active Abandoned
- 2018-02-01 MX MX2019009070A patent/MX2019009070A/es unknown
- 2018-02-01 JP JP2019541287A patent/JP2020514321A/ja active Pending
- 2018-02-01 BR BR112019015797-2A patent/BR112019015797A2/pt not_active Application Discontinuation
- 2018-02-01 KR KR1020197025725A patent/KR20190110612A/ko not_active Ceased
- 2018-02-01 WO PCT/US2018/016510 patent/WO2018144775A1/en not_active Ceased
- 2018-02-01 CA CA3051252A patent/CA3051252A1/en active Pending
- 2018-02-01 CN CN201880018964.5A patent/CN110430894A/zh active Pending
- 2018-02-01 CN CN202311184702.5A patent/CN117224710A/zh active Pending
- 2018-02-01 SG SG11201906969PA patent/SG11201906969PA/en unknown
-
2019
- 2019-02-19 US US16/279,372 patent/US10881730B2/en active Active
- 2019-07-30 CL CL2019002134A patent/CL2019002134A1/es unknown
- 2019-07-30 MX MX2022011934A patent/MX2022011934A/es unknown
- 2019-07-30 IL IL268361A patent/IL268361A/en unknown
- 2019-08-27 CO CONC2019/0009234A patent/CO2019009234A2/es unknown
-
2020
- 2020-11-18 US US16/951,092 patent/US20210128721A1/en not_active Abandoned
-
2023
- 2023-04-19 JP JP2023068492A patent/JP2023103250A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514321A5 (enExample) | ||
| JP2020506189A5 (enExample) | ||
| Thongchot et al. | Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy | |
| US20220306688A1 (en) | KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto | |
| TWI641385B (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP7372253B2 (ja) | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ | |
| JP2020521478A5 (enExample) | ||
| JP2019527231A (ja) | がんを治療するための組み合わせ | |
| EP4319751A1 (en) | Therapeutic compositions and methods for treating tumors | |
| CN114761009A (zh) | 具有失调的成纤维细胞生长因子受体信号转导的癌症的靶向治疗 | |
| CN112587666A (zh) | 用于治疗癌症的pd-1/pd-l1相互作用的小分子抑制剂和抗pd-1抗体的组合 | |
| JP2018527333A5 (enExample) | ||
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| He et al. | Discovery of a novel EGFR-targeting antibody–drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies | |
| CA3074985A1 (en) | Compounds and methods for treating cancer | |
| CN114514025A (zh) | 新颖的治疗 | |
| CN104837814B (zh) | 新型化合物及其用途 | |
| Ooi et al. | RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update | |
| JP2025041742A (ja) | 薬学的組合せ | |
| JPWO2021263026A5 (enExample) | ||
| US20250326846A1 (en) | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor | |
| TW202340142A (zh) | Ｇｃｌ抑制劑 | |
| JP2023552368A (ja) | Ｙボックス結合タンパク質１阻害剤 | |
| EP4204592A1 (en) | Methods of treating cancer by administering a pd-1 inhibitor | |
| CN114163479A (zh) | 一类治疗癌症用的铂类化合物及其制备方法 |